EP0442961A4 - Hybrid procoagulant proteins - Google Patents

Hybrid procoagulant proteins

Info

Publication number
EP0442961A4
EP0442961A4 EP19890913253 EP89913253A EP0442961A4 EP 0442961 A4 EP0442961 A4 EP 0442961A4 EP 19890913253 EP19890913253 EP 19890913253 EP 89913253 A EP89913253 A EP 89913253A EP 0442961 A4 EP0442961 A4 EP 0442961A4
Authority
EP
European Patent Office
Prior art keywords
proteins
hybrid
procoagulant proteins
disclosed
peptide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19890913253
Other versions
EP0442961A1 (en
EP0442961B1 (en
Inventor
Randal J. Kaufman
Debra D. Pittman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of EP0442961A1 publication Critical patent/EP0442961A1/en
Publication of EP0442961A4 publication Critical patent/EP0442961A4/en
Application granted granted Critical
Publication of EP0442961B1 publication Critical patent/EP0442961B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Hybrid procoagulant proteins are disclosed which contain peptide sequences of human blood coagulation factors V and VIII. DNA molecules encoding these proteins and materials and methods for expressing them are also disclosed. Preferably, peptide sequence in the B domain of Factor VIII is replaced with peptide sequence derived from human Factor V.
EP89913253A 1988-11-14 1989-11-14 Hybrid procoagulant proteins Expired - Lifetime EP0442961B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US270882 1988-11-14
US07/270,882 US5004803A (en) 1988-11-14 1988-11-14 Production of procoagulant proteins
PCT/US1989/005049 WO1990005530A1 (en) 1988-11-14 1989-11-14 Hybrid procoagulant proteins

Publications (3)

Publication Number Publication Date
EP0442961A1 EP0442961A1 (en) 1991-08-28
EP0442961A4 true EP0442961A4 (en) 1992-04-08
EP0442961B1 EP0442961B1 (en) 1994-11-02

Family

ID=23033233

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89913253A Expired - Lifetime EP0442961B1 (en) 1988-11-14 1989-11-14 Hybrid procoagulant proteins

Country Status (7)

Country Link
US (1) US5004803A (en)
EP (1) EP0442961B1 (en)
JP (1) JPH04501508A (en)
AT (1) ATE113475T1 (en)
AU (1) AU4644689A (en)
DE (1) DE68919229T2 (en)
WO (1) WO1990005530A1 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
JP4236698B2 (en) * 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー Expression of PACE in host cells and uses thereof
CA2078721A1 (en) * 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU5602394A (en) * 1992-11-13 1994-06-08 Duke University Chimeric blood coagulation proteins
JPH08511423A (en) 1993-06-10 1996-12-03 ジェネティック セラピー，インコーポレイテッド Adenovirus vector for treatment of hemophilia
GB9413035D0 (en) * 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
AU6291896A (en) * 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
EP1754718B1 (en) * 1996-04-24 2011-03-23 The Regents Of The University Of Michigan Inactivation resistant factor VIII
US6270973B1 (en) 1998-03-13 2001-08-07 Promega Corporation Multiplex method for nucleic acid detection
US6312902B1 (en) 1998-03-13 2001-11-06 Promega Corporation Nucleic acid detection
US6235480B1 (en) 1998-03-13 2001-05-22 Promega Corporation Detection of nucleic acid hybrids
US6270974B1 (en) 1998-03-13 2001-08-07 Promega Corporation Exogenous nucleic acid detection
US6268146B1 (en) 1998-03-13 2001-07-31 Promega Corporation Analytical methods and materials for nucleic acid detection
US6335162B1 (en) 1998-03-13 2002-01-01 Promega Corporation Nucleic acid detection
US6703211B1 (en) 1998-03-13 2004-03-09 Promega Corporation Cellular detection by providing high energy phosphate donor other than ADP to produce ATP
US7090975B2 (en) 1998-03-13 2006-08-15 Promega Corporation Pyrophosphorolysis and incorporation of nucleotide method for nucleic acid detection
US6391551B1 (en) 1998-03-13 2002-05-21 Promega Corporation Detection of nucleic acid hybrids
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
WO2000024759A1 (en) * 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
CA2357011A1 (en) * 1999-02-18 2000-08-24 Promega Corporation Multiplex method for nucleic acid detection
AU2002248329B2 (en) * 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
WO2003047507A2 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
EP3910063A1 (en) 2003-09-30 2021-11-17 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US20060080848A1 (en) * 2004-10-19 2006-04-20 Lace Charles R Wheel blade sight
EP2359865B1 (en) 2005-04-07 2013-10-02 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
US20080070251A1 (en) * 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
CA2756197A1 (en) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Factor viii variants and methods of use
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
PT2506868T (en) 2009-12-06 2018-02-23 Bioverativ Therapeutics Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
MX342858B (en) 2010-03-29 2016-10-13 The Trustees Of The Univ Of Pennsylvania * Pharmacologically induced transgene ablation system.
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
JP6224459B2 (en) 2011-02-17 2017-11-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer
PL2717898T3 (en) 2011-06-10 2019-06-28 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
EP3513804B1 (en) 2011-07-08 2022-03-23 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
EA029560B1 (en) 2012-01-12 2018-04-30 Байоджен Эмэй Инк. Use of chimeric blood coagulation factor for reducing inhibitory immune response in a subject
MX357403B (en) 2012-01-12 2018-07-09 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof.
CN104487452A (en) 2012-02-15 2015-04-01 阿穆尼克斯运营公司 Factor viii compositions and methods of making and using same
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
DK2882450T3 (en) 2012-07-11 2020-02-24 Bioverativ Therapeutics Inc FACTOR VIII COMPLEX WITH XTEN AND VON WILLEBRAND FACTOR PROTEIN AND USES THEREOF
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
US9914764B2 (en) 2013-03-15 2018-03-13 Bayer Healthcare, Llc Variant factor VIII polypeptides and methods of their production and use
US9623088B2 (en) 2013-03-15 2017-04-18 Bioverativ Therapeutics Inc. Factor VIII polypeptide formulations
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
CN106456718A (en) 2014-01-10 2017-02-22 比奥根Ma公司 Factor viii chimeric proteins and uses thereof
ES2763551T3 (en) 2015-04-16 2020-05-29 Univ Emory Recombinant promoters and vectors for liver protein expression and use
EA201890423A1 (en) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION
KR20210020030A (en) 2018-05-18 2021-02-23 바이오버라티브 테라퓨틱스 인크. How to treat hemophilia A
KR20230042754A (en) 2020-08-07 2023-03-29 아미쿠스 세라퓨틱스, 인코포레이티드 Vesicle Targeting Proteins and Uses Thereof

Also Published As

Publication number Publication date
DE68919229T2 (en) 1995-05-24
WO1990005530A1 (en) 1990-05-31
JPH04501508A (en) 1992-03-19
ATE113475T1 (en) 1994-11-15
US5004803A (en) 1991-04-02
EP0442961A1 (en) 1991-08-28
AU4644689A (en) 1990-06-12
DE68919229D1 (en) 1994-12-08
EP0442961B1 (en) 1994-11-02

Similar Documents

Publication Publication Date Title
EP0442961A4 (en) Hybrid procoagulant proteins
DK0672138T3 (en) Chimeric procoagulant proteins
ES2147178T3 (en) DOMAIN OF UNION TO CD2 OF THE ANTIGEN 3 ASSOCIATED WITH THE LYMPHOCYTIC FUNCTION.
DE69034253D1 (en) Hybrid immunoglobulins for use in therapeutic procedures
GR1000083B (en) Mycetobacterial products derived from recompositions and peptides
GR3030811T3 (en) Proteins produced by human lymphocytes, dna sequence coding these proteins, and pharmaceutical and biological uses thereof
DE68928934D1 (en) METHOD FOR PRODUCING HUMAN DNASE
EP0787802A3 (en)
ATE119915T1 (en) DNA SEQUENCES, RECOMBINANT DNA MOLECULES AND METHOD FOR PRODUCING MULLERIAN INHIBITING SUBSTANCE-LIKE POLYPEPTIDES.
IL88293A0 (en) Alveolar surfactant proteins
ES8704207A1 (en) Rhinovirus strain HRV2 polypeptides and DNA molecules encoding them.
EP0960117A4 (en) FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTORS (FHFs) AND METHODS OF USE
DE68923496D1 (en) Process for the production of motilin-like polypeptides and its expression.
EP0315081A3 (en) Anti-coagulating protein pp4-x, its preparation and use
ATE300554T1 (en) CONNECTIVE TISSUE GROWTH FACTOR 3.
EP0723016A3 (en) Activating factor of leukocytes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910513

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19920220

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930521

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19941102

Ref country code: LI

Effective date: 19941102

Ref country code: BE

Effective date: 19941102

Ref country code: NL

Effective date: 19941102

REF Corresponds to:

Ref document number: 113475

Country of ref document: AT

Date of ref document: 19941115

Kind code of ref document: T

ITF It: translation for a ep patent filed

Owner name: JACOBACCI CASETTA & PERANI S.P.A.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19941130

REF Corresponds to:

Ref document number: 68919229

Country of ref document: DE

Date of ref document: 19941208

ET Fr: translation filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20081008

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20081118

Year of fee payment: 20

Ref country code: SE

Payment date: 20081107

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20081106

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20081128

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20081008

Year of fee payment: 20

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20091113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20091113